Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)
Phase 3positivesefaxersenPositive
AI Analysis
Summary
Roche announced positive interim results from the Phase 3 IMAgINATION study showing sefaxersen achieved statistically significant proteinuria reduction compared to placebo in adults with IgA nephropathy. The drug met its primary endpoint with a favorable safety profile and no new safety signals.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Met primary endpoint with statistically significant and clinically meaningful proteinuria reduction compared to placebo at 37 weeks as measured by 24-hour urine protein-to-creatinine ratio (UPCR)
Importance:8/10
Sentiment:
0.85
Phase 3 dataNephrologyKidney diseasePositive resultsPrimary endpoint metProteinuria reduction
Related Companies
Read the original article
Published by GlobeNewswire Pharma on September 23, 2026 5:15 AM